Brazil Pharma and Healthcare Sector Report 2025-2026

In 2024-2025, Brazil witnessed significant investments in its pharmaceutical and healthcare sector. Specifically, the Brazilian National Development Bank (BNDES) allocated record-high loans to domestic pharmaceutical manufacturing firms Ache and Eurofarma, thereby supporting projects in generic and innovative drugs development, research & development (R&D), and new manufacturing plants. Moreover, real estate investment funds (FIIs) diversified into healthcare infrastructure, financing hospital developments such as Sabara's child hospital and the new oncology centre in São Paulo. Additionally, other domestic pharmaceutical companies expanded their manufacturing capacity, including Libbs which inaugurated advanced production facilities for biotechnological drugs, while EMS launched new diabetes and obesity medications product lines following patent expirations. Furthermore, public healthcare infrastructure also advanced with the inauguration of Brazil's first public palliative care hospital in Salvador, and a 45% y/y increase in 2024 in the number of public hospitals with high-quality intensive care units (ICUs), thus reflecting nationwide healthcare improvements.

This report provides a complete and detailed analysis of the "Healthcare and pharma" sector for Brazil. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Healthcare and pharma" sector in Brazil
• Crystallise the forces both driving and restraining this sector in Brazil
• Ascertain Brazil’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Brazil.
• Build a clear picture of trends, output and consumption for specific sub-sectors